ScripBayer’s hopes of catching up with Boehringer Ingelheim’s small molecule HER2 inhibitor zongertinib have been boosted by regulators in the US putting sevabertinib, its same-class candidate for lung can
ScripWhile significant progress has been made in the treatment of non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) has seen fewer advances and patients continue to have limited treatment o
ScripBefore life sciences companies reported first-quarter earnings, a jump in sales might have been expected as companies and patients stocked up ahead of tariffs. But in the event, this was less pronounc
ScripThe 2025 American Society of Clinical Oncology conference will take place in Chicago from 30 May-3 June, and while it typically leans toward solid tumors, it also often features a number of important